Sign up USA
Proactive Investors - Run By Investors For Investors

GlycoMimetics shares surge on positive news on acute myeloid leukemia candidate

In the trial, patients treated with the drug, combined with chemotherapy, continue to experience higher-than-expected remission rates
GlycoMimetics shares surge on positive news on acute myeloid leukemia candidate
The firm released positive data on from its ongoing Phase 2 clinical trial of GMI-1271

GlycoMimetics Inc (NASDAQ: GLYC) shares shot up over 88% to $10.14 as it release positive data on from its ongoing Phase 2 clinical trial of its product candidate GMI-1271 in patients with acute myeloid leukemia (AML).

Yesterday, the group announced that the US Food and Drug Administration (FDA) had granted 'Breakthrough Therapy designation for the same candidate.

The data will be presented at the June annual meetings of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA).

In the trial, patients treated with the drug, combined with chemotherapy, continue to experience higher-than-expected remission rates and lower-than-expected induction-related mortality rates in both arms of the trial.

Helen Thackray, Chief Medical Officer, said:  “The data has consistently shown good tolerability and high remission rates as well as lower than expected 30- and 60-day mortality rates in early evaluations of patients.

"We are increasingly confident that our investigational drug, GMI-1271, may play a role in addressing unmet needs in this cancer. 

Giles_55af4ddca6481.jpg


Register here to be notified of future GLYV Company articles
View full GLYV profile View Profile

Related Articles

shutterstock_139366595.jpg
January 25 2017
The company's update reveals a company in rude health
Netscientific has its thumbs in a few clinical pies
March 31 2017
The firm commercialises intellectual property (IP) through developing early and mid-stage healthcare firms
a child with asthma using an inhaler
September 22 2016
Phase II results for its prospective asthma treatment are due next year, while its LOXL2 collaboration with Pharmaxis is set for a Phase I trial in 2017
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use